Biosimilars: a new era in access to breast cancer treatment

For the first time, on Dec 18, 2019, WHO granted “prequalification” status to a biosimilar drug, for the treatment of breast cancer. Distinct from generics, biosimilars are interchangeable biological...

thelancet.com